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Introduction: The aim of this study was to evaluate the efficacy and
safety of Erlotinib in Japanese patients with previously treated non-small
cell lung cancer (NSCLC). Available tumor biopsy samples were analyzed
to examine relationships between biomarkers and clinical outcome.
Methods: This open-label phase II trial enrolled stage III/IV
NSCLC patients who had progressive disease after at least one prior
platinum-based chemotherapy regimen. Erlotinib was administered
at a dose of 150 mg/d orally until disease progression or intolerable
toxicity. Analysis of epidermal growth factor receptor gene muta-
tions in exon 18–21 by direct sequencing was performed in tumor
tissue specimens obtained at the first diagnosis.
Results: Sixty-two patients were enrolled and 60 patients were
evaluable for efficacy. Objective response rate and disease control
rate were 28.3% and 50.0%; median time to progression and overall
survival were 77 days and 14.7 months, respectively. In logistic
regression analysis, only smoking history was proved to be a statisti-
cally significant predictive factor for response (odds ratio: 0.06, p 
0.001). Only 7 patients had samples available for mutation analysis.
Three patients who had deletion mutations on exon 19 (del E746-A750
or del S752-I759) exhibited objective response. Common toxicities
were rash (98%), dry skin (81%), and diarrhea (74%). Discontinuation
due to adverse events occurred in 11 patients (18%). Four patients (6%)
experienced interstitial lung disease-like events, one of whom died.
Conclusion: Erlotinib is efficacious in Japanese patients with pre-
viously treated NSCLC. The toxicity profile was similar to that in
Western patients, except for a somewhat higher incidence of skin
disorders and interstitial lung disease. Further studies are needed to
determine the relationship between epidermal growth factor receptor
mutations and outcomes with Erlotinib in Japanese patients.
Key Words: Non-small cell lung cancer, Erlotinib, Molecular target
therapy, EGFR-TKIs, EGFR mutation.
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Lung cancer affects approximately 1.2 million people an-nually, and is the leading cause of cancer death in the
world.1 More than 80% of affected patients are diagnosed
with non-small cell lung cancer (NSCLC). The standard
first-line treatment for metastatic NSCLC is a combination of
platinum chemotherapy with a third-generation agent such as
docetaxel, paclitaxel, gemcitabine, vinorelbine, and irinote-
can.2,3 Although patients with stage II, IIIA, or IIIB NSCLC
receive platinum-based chemotherapy as part of combined
modality treatment with thoracic radiotherapy or surgery,
many will be candidates for second or third-line chemother-
apy. Docetaxel is the only cytotoxic agent with a proven
survival advantage over supportive care in patients with
disease progression after cisplatin-based chemotherapy for
NSCLC.4 The other agent for which a survival benefit has
been demonstrated in this setting is erlotinib,5 which was
approved in Japan for the treatment of relapsed NSCLC in
October 2007. Erlotinib is a selective, orally active epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
In contrast to the experience with the cytotoxic chemothera-
peutic agents, response to treatment with EGFR-TKIs has
been reported to be influenced by gender, histological type,
race or ethnic origin, and smoking status.5–8
Tumor molecular markers, including EGFR gene mu-
tations and protein expression, have been widely studied in
patients with NSCLC, and there is strong evidence that the
presence of EGFR gene mutations is a predictor of tumor
response and resistance.9–12 However, few prospective stud-
ies have evaluated molecular markers as predictors of out-
come, and their clinical usefulness is unproven.
This report presents the results of the first phase II study
of erlotinib conducted in Japanese patients with NSCLC. The
purpose was to evaluate the efficacy and safety of erlotinib in
this population. Where available, tumor biopsy samples were
analyzed for EFGR-related markers.
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PATIENTS AND METHODS
This phase II, multicenter, open-label study recruited
patients at 11 hospitals in Japan. The primary end point was
the objective response rate (ORR) to erlotinib treatment (150
mg/d). Secondary endpoints were disease control rate (DCR),
response duration, time to progression, overall survival (OS),
quality of life (QoL), and safety. The protocol was approved
by the ethics review boards of all participating institutions,
and conducted in accordance with Japanese Good Clinical
Practice guidelines.
Patient Selection
Patients with histologically or cytologically docu-
mented stage IIIB or IV NSCLC at study entry (not curable
with surgery or radiotherapy) that was recurrent or refractory
to treatment with one or more chemotherapy regimens (in-
cluding at least one platinum-containing regimen), were en-
rolled into this study. Additional eligibility criteria included:
the presence of measurable lesions by Response Evaluation
Criteria in Solid Tumors (RECIST); age 20, 75 years;
Eastern Cooperative Oncology Group performance status
(ECOG PS) of 0–2, and adequate bone marrow, hepatic, and
renal function, i.e., aspartate aminotransferase and alanine
aminotransferase (ALT) levels 2.5 times the upper limit of
normal and total bilirubin of 1.5 times the upper limit of
normal. Patients with existing or previous interstitial lung
disease (ILD) were excluded, although a history of radiation
pneumonitis (limited to the field of radiation treatment) was
permitted. Concomitant anticancer treatment and prophylac-
tic medication for adverse events (AEs) were not permitted,
nor was prior use of anti-EGFR or anti human epidermal
growth factor receptor (HER2) agents (small molecules and
monoclonal antibodies). Written informed consent was ob-
tained from all patients.
Treatment Procedure
After completion of the baseline assessments (see be-
low), all patients received erlotinib (150 mg orally) each
morning, 1 hour before breakfast, until the occurrence of
progressive disease (PD) or unacceptable toxicity (all AEs
were graded using the National Cancer Institute Common
Toxicity Criteria Version 2.0). In the event of treatment-
related toxicity, 2 dose reductions of 50 mg were permitted
per patient, and dosing could also be interrupted for up to 14
days. For grade 3 or intolerable grade 2 rash, treatment was
withheld until the rash improved to grade 2 or less, when a
lower dose of erlotinib was initiated. For grade 3 diarrhea,
treatment was withheld until the diarrhea was grade 1 or less,
when a lower dose was started. For ILD of any grade, or any
grade 4 toxicity, treatment was immediately and permanently
discontinued.
Evaluation of Efficacy
Objective tumor response was assessed in accordance
with RECIST.13 Tumor assessments were performed at base-
line, then every 4 weeks until week 16, and then every 8
weeks thereafter. Confirmation of complete or partial re-
sponses (PR) was required, by means of a second assessment
conducted 28 days or more after the initial assessment. Stable
disease (SD) was defined as disease control (absence of
progression) maintained for at least 6 weeks. An independent
response evaluation committee consisting of 2 oncologists
and a radiologist reviewed images of patients with complete
response, PR, and SD. Individual survival times were deter-
mined from the survival status of each patient during the
study period and at the post study follow-up survey con-
ducted in June-July 2005 and May-July 2006. OS was defined
as the time from first administrated to death.
Quality of Life Evaluation
The Functional Assessment of Cancer Therapy-Lung
(FACT-L) questionnaire (Version 4-A)14 was used to assess
QoL. The full FACT-L questionnaire was administered at
baseline and then every 28 days. In addition, the Lung Cancer
Subscale (LCS), an independently validated component of
FACT-L, was administered weekly during the treatment pe-
riod. Best responses on the LCS were analyzed for all patients
with a baseline LCS score of 24 or less (out of a possible 28
points) and symptomatic improvement was defined as an
increase from the baseline score of 2 or more points, sus-
tained for at least 4 weeks.
Evaluation of Safety
Baseline assessment included a full patient history,
physical examination, standard laboratory tests, electrocardi-
ography, chest radiography, pregnancy test, and ophthalmo-
logic tests (vision test and slit-lamp examination). Every
week until week 8 and every 2 weeks thereafter, vital signs
and ECOG PS were monitored and blood samples were taken
for hematology and blood chemistry tests. A radiograph
examination to assess pulmonary toxicity was conducted
weekly until week 4 and every 2 weeks thereafter. Ophthal-
mologic examinations were repeated at week 8 and at the end
of the study. Observation and evaluation of AEs was con-
ducted as appropriate throughout the study period. All AEs
were graded using National Cancer Institute Common Tox-
icity Criteria Version 2.0. For all ILD-like events, the data
safety monitoring board (which consisted of oncologists and
pneumonologists) reviewed the clinical data and images; the
images were also examined by a review committee of radi-
ologists with expertise in drug-induced pulmonary disorders.
Biomarker Analysis
EGFR mutations and EGFR and HER2 protein expres-
sion were assessed in patients with suitable tumor tissue
specimens at first diagnosis or surgery; these assessments
were done only with separate written consent. Tumor samples
were obtained from each center as formalin-fixed and paraf-
fin-embedded blocks, or as thinly sliced tissue sections
mounted on glass microscope slides. For the mutation anal-
ysis, the tissue was microdissected by Targos Molecular
Pathology (Kassel, Germany) and direct sequencing was
conducted at the Roche Centre of Medical Genomics (Basel,
Switzerland), using a nested polymerase chain reaction of
exon 18–21. EGFR protein expression was analyzed by Lab
Corp (Mechelen, Belgium). EGFR expression analysis was
conducted by immunohistochemistry using Dako EGFR
PharmDx™ kits (Dako, Carpinteria, CA). A positive test was
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defined as membranous staining in 10% of the tumor cells.
HER2 protein expression was measured using HercepTest™
(Dako, Carpinteria, CA), and a score of 1 or above (possi-
ble scores were: 0, 1, 2, 3) was regarded as positive.
Statistical Analysis
Given an expected ORR of 20%, a Fisher’s exact test
was performed (one-sided   2.5%). Based on 50 patients,
the power to test the null hypothesis (ORR  5%) was
89.66%. The target sample size of 60 patients was chosen on
the expectation that a proportion of patients would prove to
be ineligible for the study. The main analysis of efficacy was
conducted on the full analysis set (FAS), which was produced
by omitting ineligible patients. The 95% confidence interval
(CI) for ORR, DCR, and symptom improvement rate was
calculated by the Clopper-Pearson method. The time-to-event
variables were estimated by the Kaplan-Meier method. Lo-
gistic regression and Cox proportional hazards regression
analysis was conducted on best response and survival time,
respectively. In both cases, univariate and multivariate anal-
yses were used to evaluate the effects of 11 factors relating to
patient and disease characteristics, and previous treatment.
RESULTS
Patient Characteristics
A total of 62 patients were enrolled between December
2003 and January 2005. All were evaluable for safety and 60
were evaluable for efficacy (FAS). Two patients did not have
a measurable lesion according to RECIST. The baseline
characteristics of the patients, including their treatment his-
tory, are shown in Table 1. The median age was 60.5 years
(range: 28–74 years), and 71% of patients were male. Fifty-
seven patients (92%) had adenocarcinoma, and 20 (32%)
were never-smokers. Twenty-seven patients (44%) had re-
ceived only one previous chemotherapy regimen.
Efficacy
Tumor response rates in the FAS (as assessed by
extrainstitutional review) are shown in Table 2. Seventeen
patients were assessed as having a PR and 13 as having SD.
The ORR was 28.3% (95% CI: 17.5–41.4%) and the DCR
was 50% (95% CI: 36.8–63.2%). In three patients, objective
response could not be adequately confirmed, because each
discontinued treatment early in the study due to AEs. The
median duration of response was 278 days (95% CI: 203–422
days), and time to progression was 77 days (95% CI: 55–166
days). OS was determined based on information collected
until the follow-up survey conducted in May–July 2006. The
median survival time was 14.72 months (95% CI: 11.07–
20.57 months; 19 censored cases) and the 1-year survival rate
was 56.5% (95% CI: 43.9–69.1%) (Figure 1). The median
OS of patients with PD was 9.95 months. The symptom
improvement rate measured using the LCS was 42.1% (24/
57; 95% CI: 29.1–55.9%).
The overall response rate was higher in women (58.8%;
10/17) than in men (16.3%; 7/43, 2 test: p  0.0029), and in
never-smokers (63.2%; 12/19) than in current or former
smokers (12.2%; 5/41, p  0.0002). There was no statisti-
cally significant difference between the response rate in
patients with adenocarcinoma (28.6%; 16/56) and nonadeno-
carcinoma histology (25.0%; 1/4, p  1.0000). The response
TABLE 1. Summary of Baseline Patient Characteristics and
Demographics
Patient and Disease characteristics
No. of Patients



















Never smoked 20 32
Current- or former smoker 42 68










Time since last regimen (d)
Median 80.0
Range 29–528
TABLE 2. Response Assessment
Parameter n (%)
Partial response 17 28.3
Stable disease 13 21.7
Progressive disease 27 45.0
Not assessable 3 5.0
Response rate (%) (95% CI) 28.3 (17.5–41.4)
Disease control rate (%) (95% CI) 50.0 (36.8–63.2)
Duration of response (median: days)a
(95% CI)
278 (203.0–422.0)
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rate was not affected by the number of previous chemother-
apy regimens, however, being 27% for patients with one
previous regimen (7/26) and 29% for those with 2 or more
regimens (10/34). No statistically significant differences were
found between other patient subgroups. In a multivariate
logistic regression analysis, only smoking history was found
to be a statistically significant predictor of response. A mul-
tivariate Cox regression analysis showed that both smoking
history and ECOG PS were significant predictors for OS
(Table 3).
Safety
All 62 patients who received erlotinib were assessed for
safety. Treatment-related AEs were observed in all patients,
and there were 24 serious AEs in 18 patients (29%). AEs led
to discontinuation of erlotinib in 11 patients (18%), including
3 due to ILD-like events, 2 due to ALT elevation, and one
each due to rash, paronychia, punctate keratitis, dyspnea/
hypoxia, pneumonia and fever/inflammatory neck swelling,
and to dose interruptions in 30 patients (48.4%). While the
main reasons for the dose interruptions were rash (n  15;
24.2%) and diarrhea (n 4; 6.5%), only one patient with rash
FIGURE 1. Kaplan-Meier plot showing overall survival.
TABLE 3. Logistic and Cox Regression Analysis
Odds Ratiob (95% CI) p
Logistic regression analysis of response
Univariate analysis
Sex (female vs male) 0.14 0.04–0.48 0.002
Age (65 vs 65) 1.26 0.38–4.13 0.704
Histology (non-AD vs AD) 1.20 0.12–12.41 0.878
Smoking history (never vs current or former) 0.08 0.02–0.30 0.001
Performance status (0 vs 1) 0.62 0.19–1.98 0.420
Prior regimens (1 vs 2) 1.13 0.36–3.53 0.832
Stage (IIIB vs IV) 0.99 0.17–5.65 0.988
KL-6 (baseline) (median 496.5 U/mla vs median) 1.64 0.53–5.12 0.392
Best response to previous chemotherapy (non-PR vs PR) 0.90 0.24–3.33 0.869
Prior taxanes (no vs yes) 0.43 0.10–1.84 0.253
Time since initial diagnosis (12 mo vs 12 mo) 1.02 0.31–3.30 0.976
Multivariate analysis
Smoking history (never vs current or former) 0.06 0.02–0.28 0.001
Time since initial diagnosis (12 mo vs 12 mo) 2.22 0.49–10.20 0.304
Cox regression analysis of survival
Univariate analysis
Sex (female vs male) 1.76 0.85–3.61 0.126
Age (65 vs 65) 0.86 0.44–1.71 0.675
Histology (non-AD vs AD) 0.55 0.19–1.55 0.255
Smoking history (never vs current or former) 1.90 0.93–3.90 0.079
Performance status (0 vs 1) 2.31 1.12–4.73 0.023
Prior regimens (1 vs 2) 0.93 0.50–1.75 0.833
Stage (IIIB vs IV) 1.38 0.49–3.89 0.542
KL-6 (baseline) (median 496.5 U/mla  vs median) 1.64 0.87–3.06 0.125
Best response to previous chemotherapy (non-PR vs PR) 0.66 0.31–1.44 0.300
Prior taxanes (no vs yes) 2.09 0.74–5.90 0.163
Time since initial diagnosis (12 mo vs 12 mo) 0.76 0.40–1.47 0.418
Multivariate analysis
Smoking history (never vs current or former) 2.20 1.06–4.56 0.035
Performance status (0 vs 1) 2.59 1.25–5.37 0.011
a Or 629 ng/ml.
b Left site of ‘vs’ indicates reference group.
PR, partial response; AD, adenocarcinoma; CI, confidence interval.
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had to discontinue treatment, and no patients had to discon-
tinue because of diarrhea or any other digestive toxicity.
Fourteen patients (23%) had dose reductions due to AEs,
mostly due to rash (n 9; 15%). Treatment-related AEs with
an incidence of 20% or more are shown in Table 4; the main
events were rash (98%), dry skin (81%), and diarrhea (74%).
Elevated laboratory test values related to liver function were
found in some patients (total bilirubin: 24%, ALT: 24%), and
grade 3 ALT elevation led to treatment discontinuation in 2
patients. Four patients had ILD-like events, including wors-
ening of radiation pneumonitis in one patient, and one died
(Table 4). All four (three men; one woman) had an ECOG PS
of 0–1 and 2 were former smokers. The patient who died was
a 67-year-old man with adenocarcinoma and no history of
smoking who discontinued treatment on day 84 due to PD.
He developed interstitial pneumonia on day 103 and received
3 days of palliative thoracic irradiation from day 99, after
completing the study (3 Gy  3 days). A computed tomog-
raphy scan showed characteristic features of ILD (crypto-
genic organizing pneumonia-like pattern), and the ILD re-
view committee decided that use of erlotinib could not be
excluded as the cause. For the patient with worsening of
radiation pneumonitis (case 4), the committee concluded that
there was a possible influence of previous radiation therapy,
and that this could be seen in the computed tomography scan
on day 1. There was, therefore, little reason to suspect that the
use of erlotinib had been the cause. Rather, it appeared that
the radiation pneumonitis had worsened according to the
normal course of illness.
Biomarker Analysis
Tissue samples for measurement of EGFR mutations
were available for 16 of the 60 patients evaluated for efficacy.
For 7 patients, all base sequences were successfully identified
in the 4 segments of exons 18–21. All seven (three men, four
women) had adenocarcinoma; three were never-smokers,
three former smokers and one a current smoker. Three had
PR, two SD and two PD. Five of the seven patients had EGFR
gene mutations and, in all, seven different mutations were
detected. The 3 patients with PR all had deletion mutations in
exon 19 (del E746-A750 or del S752-I759). One of the 2
patients with PD had no mutations and the other had 2
substitution mutations: L858R in exon 21 and the resistance
mutation T790M in exon 20 (Table 5).
Paraffin-embedded tissue samples for immunohisto-
chemistry were available from 12 patients, among whom, 11
had successful determinations of immunohistochemical stain-
ing (including 3 patients with PR). Six of the 11 were found
to be EGFR-positive and 4 were HER2-positive. However,
there were no notable relationships between the EGFR and
HER2 expression status and either tumor response or patient
characteristics such as sex, histological type or smoking
history (data not shown).
DISCUSSION
The present study was conducted on the basis of results
from a phase I study of erlotinib in Japanese patients with
solid tumors,15 which showed erlotinib to be well tolerated at
TABLE 4. Major Treatment-Related Adverse Events and Interstitial Lung Disease-Like Events
Eventa n %
NCI-CTC Grade (n)
1 2 3 >4
Rash 61 98.4 18 41 2 0
Dry skin 50 80.6 44 6 — —
Diarrhea 46 74.2 33 10 3 0
Pruritus 45 72.6 38 7 0 —
Stomatitis 24 38.7 19 4 1 0
Fatigue 21 33.9 15 6 0 0
Anorexia 19 30.6 11 6 2 0
Paronychia 18 29.0 12 5 1 0
C-reactive protein increased 15 24.2 8 7 0 0
Alanine aminotransferase increased 15 24.2 11 2 2 0
Total bilirubin increased 15 24.2 8 7 0 0
Weight loss 13 21.0 13 0 0 —
ILD-like events 4 6.5 1 0 2 1b




Status Histology Onset (day) Outcome Relation to Erlotinibc
1 Male 75 Former 640 1 Adenocarcinoma 52 Recovery Probable
2 Male 67 Never — 1 Adenocarcinoma 103 Death (145) Possible
3 Female 39 Never — 0 Adenocarcinoma 85 Recovery Probable
4 Male 69 Former 1000 1 Adenocarcinoma 13 Recovery Unlikely
a Categorized by MedDra Ver.7.1 (except for event).
b Grade 5.
c Judged by ILD review committee.
NCI-CTC, National Cancer Institute Common Toxicity Criteria; ILD, interstitial lung disease.
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a dose of 150 mg/d, as well as a phase II study of erlotinib in
NSCLC conducted in the United States.16 In this study,
erlotinib achieved an ORR of 28.3%, which was higher than
expected, and a DCR of 50%. The response rate was higher
than that determined in the above-mentioned phase II study16
and in keeping with the rate seen in the Japanese subgroup in
the phase II study of gefitinib (IDEAL1; 27.5%).6 Assessment
of QoL using the LCS demonstrated a clinically meaningful
rate of symptom improvement of 42.1%.
The characteristics of the patients in this study were
generally similar to those of NSCLC patients as a whole, in
terms of their demographics and disease and treatment his-
tory, with the exception of a particularly high proportion of
patients with adenocarcinoma (92%). The possibility of en-
rollment bias on the basis of histological type cannot be ruled
out, in part because enrollment coincided with the emergence
of reports that the efficacy of EGFR-TKI therapy was greater
in patients with adenocarcinoma.17 However, we also ob-
served one PR and two SDs among three patients with
squamous cell carcinoma (FAS population), and our results
do not rule out the efficacy of erlotinib in any patient subtype.
A multivariate logistic regression analysis showed that smok-
ing status was significantly associated with tumor response,
in agreement with previous studies of predictive factors for
response to EGFR-TKIs.5,18,19
The median survival time with erlotinib was an encour-
aging 14.7 months. One of the reasons for this long survival
may be the high proportion of never-smokers and patients
with adenocarcinoma compared with those of other studies,
particularly the multinational phase III erlotinib study
(BR.21).5 On the other hand, the presence of EGFR gene
mutations is currently regarded as an important determinant
of treatment response to EGFR-TKIs20,21 and may be the
most important factor in relation to the favorable results seen
in the present study. However, it is important to recognize
that the potential prognostic effect of mutation status cannot
be excluded. The sample size of this and previous trials limits
the interpretation of this effect, which will be adequately
assessed only by means of appropriately powered trials spe-
cifically designed to examine these factors.
Assessment of the presence or absence of EGFR gene
mutation was possible in only seven patients in the present
study. Despite this, the results were consistent with the results
of some previous studies. All three of the patients who had a
PR (including a male current smoker) had an in-frame dele-
tion in exon 19, which is considered to be the most frequent
mutation site in the EGFR-TK domain.22 One of the 2
patients with PD had a point substitution mutation (L858R) in
exon 21, the second most frequent mutation site,22 and a point
mutation (T790M) in exon 20, which is suggested to be
involved in tolerance to EGFR-TKI.12,23,24 It would be valu-
able to conduct further prospective randomized studies on the
association between these markers and survival during treat-
ment with erlotinib in Japanese patients.
Rash and diarrhea were the main AEs reported by
patients on erlotinib treatment, as reported in previous stud-
ies.5,15,16 Rash was observed in almost all patients, and was
the main reason for treatment interruptions or dose reduc-
tions. Although the protocol allowed treatment to be inter-
rupted for grade 3 rash (or intolerable grade 2 rash), grade 3
rash only occurred in 2 patients, leading to discontinuation of
treatment in one. Most cases of rash responded to symptom-
atic treatment and either interruption or dose reduction of
erlotinib. Despite suggestions in some reports that the presence
of erlotinib-related rash is associated with treatment efficacy and
can be used to predict response,25 no supportive evidence was
found in the present study.
The incidence of ILD, which is the most clinically
problematic AE associated with erlotinib, tended to be higher
than that reported in other clinical studies of erlotinib.5,26 This
is in keeping with this class of agent, and is not unexpected
in the Japanese population.
We would recommend that careful screening of patients
for ILD risk factors, particularly signs of interstitial pneumo-
nia and pulmonary fibrosis, is done before erlotinib therapy is
initiated. Individuals with any previous history of ILD were
excluded from this study.
In conclusion, erlotinib (150 mg/d) was shown to have
promising antitumor efficacy in Japanese patients with pre-
viously treated NSCLC, leading to clinically meaningful
improvements in symptoms and an encouraging median sur-
vival time. Despite, as expected, a high rate of rash and
diarrhea, erlotinib was well tolerated at a dose of 150 mg/d by
the majority of patients.
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